Oral testing for high-risk human papillomavirus DNA and E6/E7 messenger RNA in healthy individuals at risk for oral infection.


Journal

Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236

Informations de publication

Date de publication:
01 08 2019
Historique:
received: 23 11 2018
revised: 04 03 2019
accepted: 29 03 2019
pubmed: 30 4 2019
medline: 13 5 2020
entrez: 30 4 2019
Statut: ppublish

Résumé

Testing for oral high-risk human papillomavirus (HPV) DNA may be useful for identifying individuals at increased risk for HPV-driven oropharyngeal cancer (OPC). However, positivity for HPV DNA provides no information on the transforming potential of the infection. In contrast, the detection of high-risk HPV E6/E7 messenger RNA (mRNA) may help to identify clinically significant infections because of the indispensable role of E6/E7 viral oncoproteins in the carcinogenic process. Oral rinses were collected with a mouthwash from cancer-free individuals at increased risk for oral HPV infection. High-risk HPV DNA and mRNA were evaluated via the testing of the oral rinses with the Linear Array HPV genotyping test and the Aptima HPV assay, respectively. Overall, 310 subjects with no clinical evidence of lesions of the oral cavity and oropharynx were included in the study. Thirty-three (10.6%) harbored high-risk HPV DNA in their oral rinse. These cases, together with 10 random samples negative for high-risk HPV DNA, were tested with the Aptima assay. A valid result was obtained for 41 of the 43 specimens (95.3%). Among the 31 cases that were positive for high-risk HPV DNA and had a valid Aptima result, 4 (12.9%) were positive for HPV mRNA. HPV mRNA was not detected in any of the samples negative for high-risk HPV DNA. HPV mRNA is detectable in oral rinses of cancer-free subjects. Oral HPV mRNA testing may be useful in the screening and/or early detection of HPV-driven OPC by possibly identifying active and transforming oral infections. The testing of individuals at increased risk for HPV-related OPC via simply and noninvasively collected oral specimens is an attractive option for future screening strategies.

Sections du résumé

BACKGROUND
Testing for oral high-risk human papillomavirus (HPV) DNA may be useful for identifying individuals at increased risk for HPV-driven oropharyngeal cancer (OPC). However, positivity for HPV DNA provides no information on the transforming potential of the infection. In contrast, the detection of high-risk HPV E6/E7 messenger RNA (mRNA) may help to identify clinically significant infections because of the indispensable role of E6/E7 viral oncoproteins in the carcinogenic process.
METHODS
Oral rinses were collected with a mouthwash from cancer-free individuals at increased risk for oral HPV infection. High-risk HPV DNA and mRNA were evaluated via the testing of the oral rinses with the Linear Array HPV genotyping test and the Aptima HPV assay, respectively.
RESULTS
Overall, 310 subjects with no clinical evidence of lesions of the oral cavity and oropharynx were included in the study. Thirty-three (10.6%) harbored high-risk HPV DNA in their oral rinse. These cases, together with 10 random samples negative for high-risk HPV DNA, were tested with the Aptima assay. A valid result was obtained for 41 of the 43 specimens (95.3%). Among the 31 cases that were positive for high-risk HPV DNA and had a valid Aptima result, 4 (12.9%) were positive for HPV mRNA. HPV mRNA was not detected in any of the samples negative for high-risk HPV DNA.
CONCLUSIONS
HPV mRNA is detectable in oral rinses of cancer-free subjects. Oral HPV mRNA testing may be useful in the screening and/or early detection of HPV-driven OPC by possibly identifying active and transforming oral infections. The testing of individuals at increased risk for HPV-related OPC via simply and noninvasively collected oral specimens is an attractive option for future screening strategies.

Identifiants

pubmed: 31034590
doi: 10.1002/cncr.32152
doi:

Substances chimiques

DNA, Viral 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2587-2593

Informations de copyright

© 2019 American Cancer Society.

Auteurs

Francesca Rollo (F)

Pathology Department, Regina Elena National Cancer Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Barbara Pichi (B)

Otolaryngology-Head and Neck Surgery Department, Regina Elena National Cancer Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Maria Benevolo (M)

Pathology Department, Regina Elena National Cancer Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Massimo Giuliani (M)

STI/HIV Unit, San Gallicano Dermatologic Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Alessandra Latini (A)

STI/HIV Unit, San Gallicano Dermatologic Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Laura Lorenzon (L)

Surgical and Medical Department of Translational Science, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli, Scientific Institute for Research and Healthcare, Rome, Italy.

Manuela Colafigli (M)

STI/HIV Unit, San Gallicano Dermatologic Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Mirko Frasca (M)

STI/HIV Unit, San Gallicano Dermatologic Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Raul Pellini (R)

Otolaryngology-Head and Neck Surgery Department, Regina Elena National Cancer Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Antonio Cristaudo (A)

STI/HIV Unit, San Gallicano Dermatologic Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Maria Gabriella Donà (MG)

STI/HIV Unit, San Gallicano Dermatologic Institute, Scientific Institute for Research and Healthcare, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH